Drugs / ISIS-463588
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02476019 | Jun 2015 → Jul 2016 | obesity disorder | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-12-20 | Ionis Pharmaceuticals | Regulatory Isis Initiates Phase 1 Clinical Trial of ISIS-FGFR4Rx a Peripherally Acting Drug to Treat Obesity ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1 study of ISIS-FGFR4Rx, an antisense drug designed to treat obesity. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-12-20 | Ionis Pharmaceuticals | Isis Initiates Phase 1 Clinical Trial of ISIS-FGFR4Rx a Peripherally Acting Drug to Treat Obesity ionis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS-463588 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594563 ↗ |
| Known as | IONIS-FGFR4RX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594563 ↗ |
| Known as | ISIS-FGFR4RX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02476019 ↗ |
| Action | Inhibit | “an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4” NCT02476019 ↗ |
| Modality | Antisense oligonucleotide | “an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4” NCT02476019 ↗ |
| Route | Subcutaneous | “ISIS-FGFR4RX administered subcutaneously” NCT02476019 ↗ |
| Target | FGFR4 | “an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4” NCT02476019 ↗ |